NCT07032545 Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors
| NCT ID | NCT07032545 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Maryland, Baltimore |
| Condition | Obesity and Overweight |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-12-03 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2025-12-03 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Obesity can pose significant challenges to maintaining long-term health in cancer survivors by increasing their risk of cancer coming back. Eating a healthy diet is an important way to help manage weight and improve overall health. Broccoli microgreens (BMG) are young broccoli plants packed with nutrients, and research suggests they may help prevent cancer. Previous studies in mice showed that BMG can improve gut health and metabolism, leading to better health outcomes in obese animals. This study will test whether BMG can be a useful addition to the diet of obese breast cancer (BC) survivors who have a higher risk of their cancer returning. 24 obese BC survivors will be invited to eat one serving (one cup, \~57 gram) of fresh BMG every day for two weeks. This will help understand if people can stick to this diet, how their bodies respond, and whether it affects metabolism and inflammation-two key factors linked to cancer risk. Biological markers such as body fat, glucose and lipids as well as gut bacterial changes will be analyzed to see how BMG affects individual health. This study may help create new diet strategies to improve health, reduce cancer risk, and support long-term recovery in cancer patients who are overweight or obese. In the future, this research could help doctors personalize nutrition plans to better support cancer survivors.
Eligibility Criteria
Inclusion Criteria: * Female * Had a diagnosis of breast cancer (Stage I-III) * 2 to 60 months post-curative treatment (surgery, chemotherapy, and/or radiation) * BMI \> 30 kg/m² (obese classification) * Willing to avoid cruciferous vegetables during the study * Able to sign an IRB-approved consent form Exclusion Criteria: * Have any contraindications to the proposed nutrition intervention as identified by their medical provider, their designee, or the study team (e.g., GI conditions, medication requirements, pregnancy, breastfeeding, recent history of an eating disorder). * Allergy or intolerance to cruciferous vegetables * Currently taking broccoli extract supplements
Contact & Investigator
Yuanyuan (Rose) Li, M.D., Ph.D.
PRINCIPAL INVESTIGATOR
University of Maryland
Frequently Asked Questions
Who can join the NCT07032545 clinical trial?
This trial is open to female participants only, studying Obesity and Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07032545 currently recruiting?
Yes, NCT07032545 is actively recruiting participants. Contact the research team at roseli15@umd.edu for enrollment information.
Where is the NCT07032545 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT07032545 clinical trial?
NCT07032545 is sponsored by University of Maryland, Baltimore. The principal investigator is Yuanyuan (Rose) Li, M.D., Ph.D. at University of Maryland. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.